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Summary 
The elucidation of factors that activate the impaired regeneration of the adult mammalian heart is 
of major scientific and therapeutic importance.  We found that epicardial cells contain a potent 
cardiogenic activity identified following mass spectrometric analysis as follistatin-like 1 (Fstl1). 
Epicardial Fstl1 declines following MI and is replaced by myocardial expression.  Myocardial Fstl1 
does not promote regeneration, either basally or upon transgenic overexpression. Restoration of 
FSTL1 via an epicardial patch stimulates cell cycle entry and division of pre-existing 
cardiomyocytes, improving cardiac function and survival in mouse and swine models of 
myocardial infarction. FSTL1 is the first example of an endogenous epicardial protein that 
stimulates adult mammalian heart regeneration. The data suggest that the loss of epicardial 
FSTL1 is a maladaptive response to injury, and that its restoration would be an effective way to 
reverse myocardial death and remodeling following MI in humans.   
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The epicardium of the heart is an external epithelial layer that contributes to myocardial growth 
during development by providing progenitor cells1,2 as well as mitogens, including FGFs, IGF2, 
and PDGFs3-5.  Recent studies suggest that the epicardium might also preserve function of the 
adult myocardium following injury, possibly as a source of myogenic progenitors 6,7. No epicardial-
secreted factors have shown to support adult myocardial regeneration in mammals.  
Epicardial signal activates cardiomyocyte division 
We co-cultured an epicardial mesothelial cell (EMC) line with Myh6+ mouse embryonic stem cell-
derived cardiomyocytes (referred to as mCMsESC; Extended Data Fig. 1, Suppl. Videos 1, 2, 
and Methods). Co-cultures consistently increased the number of cardiomyocytes (α-actinin+ cells, 
Fig. 1a-c) and the expression of cardiomyocyte markers (Fig. 1d). Conditioned media from EMC 
cultures recapitulated this effect (Fig. 1e-h). The number of α-actinin+ cells exhibiting rhythmic 
Ca2+ transients also increased with the addition of EMC media (8.6-fold) (Fig. 1i), as quantified 
automatically by Kinetic Imaging Cytometry, (Vala Sciences). Similarly, conditioned media 
prepared from adult epicardial-derived cells8 (Fig. 1j) increased proliferation and nearly doubled 
the incidence of Aurora B Kinase in the cleavage furrow connecting adjacent embryonic 
cardiomyocytes (Tnnt2+  cells; 0.19 to 0.33%, P < 0.05, Fig. 1k-m), indicating a secreted activity 
in the adult epicardium that promotes cytokinesis of embryonic cardiomyocytes. 
Engineered epicardium improves cardiac function after myocardial infarction 
We next evaluated the effect of epicardial-secreted factors in the adult injured heart by delivering 
conditioned media in 3D-collagen nano-fibrillar patches9. Patches were designed with an elastic 
modulus emulating the embryonic epicardium (E~12 kPa)9, lower than the mature epicardium 
(E>30-40 kPa) and fibrotic cardiac tissue (E>100 kPa), but higher than those for the most 
currently used scaffolding biomaterials (E≤1 kPa) (Fig. 1n, o). Patches seeded with EMC-media 
(33 volume %) were sutured onto the heart immediately following surgical-induced myocardial 
infarction (MI, permanent ligation of the Left Anterior Descending LAD coronary artery, Fig. 1p, 
q). Two weeks later, patch-treated hearts (both with or without EMC-media) showed improved 
morphometric parameters (Fig. 1r-t and Extended Data Table 1), consistent with collagen patch 
providing a mechanical support that inhibits remodeling9.  Notably, only patch-EMC-media 
treatment improved cardiac function (Fig. 1r, s and Extended Data Table 1).  
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Fstl1 is an epicardial factor that induces cardiomyocyte proliferation 
To identify bioactive proteins, we analyzed EMC-conditioned media by mass spectrometry. 
Comparison of spectra to the IPI rat database identified 1596 peptide reads corresponding to 311 
unique proteins.  Ten secreted proteins with the highest spectral counts were selected for testing 
in the mCMsESC assay. Of these, cardiogenic activity was noted only with Follistatin-like-1 (also 
known as Fstl1, FRP or TSC36, Accession number: NP_077345.1) (Fig. 2a). Unlike Follistatin, 
Fstl1 does not block Activin and its biochemical and biological functions are poorly 
characterized10. Fstl1 levels increase in the blood stream following acute MI and, for this reason, it 
has been considered a biomarker for acute coronary syndrome11.  
Treating mCMsESC for 8 days with bacteria-synthetized recombinant human FSTL1 (10 ng/ml) 
increased the number of cardiomyocytes (Fig. 2b-d), the transcription levels of myocardial-
specific proteins (myh6, mlc2v, and mlc2a, Fig. 2e), and the number of α-actinin+ cells with 
rhythmic Ca2+ transients (Fig. 2f). FSTL1 treatment did not induce hypertrophy. Indeed FSTL1 
decreased myocyte cell size in a dose-dependent manner (Fig. 2g) in 48 hours. Thus, FSTL1 
recapitulates the cardiomyogenic activity of the epicardial conditioned medium.  
Dynamic expression of Fstl1 after ischemic injury 
During fetal development, endogenous Fstl1 is expressed throughout the myocardium of the 
primitive heart tube12, but becomes restricted to the epicardium by mid-gestation (Fig. 2h).  
Epicardial expression persists throughout adulthood (Fig. 2i-k). Remarkably, Fstl1 localization 
shifts dramatically following ischemic injury, such that it becomes abundant in the myocardium 
(Fig. 2i-l) and absent in the epicardium and infarcted area (Fig. 2i,l).  
Epicardial reconstitution of FSTL1 promotes regeneration 
Prior studies showed that transient overexpression of Fstl1, either by myocardial transgenesis 
(Fstl1-TG13, Extended Data Fig. 2a, b) or systemic infusion, is anti-apoptotic following acute 
ischemia-reperfusion14,15.  In the context of permanent myocardial infarction, myocardial Fstl1-TG 
mice did not recapitulate the effect of the patch containing EMC-media (Extended Data Fig. 2a-j). 
We next assessed epicardial-hFSTL1 delivery by collagen patches loaded with 10 µg of 
recombinant bacterial-synthetized hFSTL1/patch. Patches retained immune-detectable hFSTL1 
up to 21 days in vitro, and 28 days in vivo, the longest times tested (Extended Data Fig. 3a-f). 
Application of hFSTL1-loaded patches simultaneously with MI significantly improved survival (Fig. 
3a) and sustained long-term recovery of cardiac function (Fig. 3b and Extended Data Table 1). 
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Epicardial patch+FSTL1 also improved cardiac function when applied onto infarcted hearts of 
Fstl1-TG mice (Fig. 3c); thus, myocardial overexpression of FSTL1 is insufficient for long-term 
recovery but epicardial reconstitution of recombinant FSTL1 is necessary to induce the beneficial 
effects.  
The improved cardiac function and survival following patch+FSTL1 treatment was accompanied 
by attenuated fibrosis (Fig. 3d-e, Extended Data Fig. 3g-j, Extended Data Table 1, and Suppl. 
Videos 3-5), increased vascularization of the patch and underlying myocardium at the border of 
the infarcted region (Fig. 3f-i), as reflected by the increased area occupied by vessels (Fig. 3f, g) 
and the increased number of vessels (of any size) per area unit (Fig. 3h, i). Masson’s trichrome 
staining showed contiguous engraftment of the patch+FSTL1 onto the host myocardium and 
demonstrated migration of host cells into the patch including evidence of striated cells (green 
arrows, last two columns in Extended Data Fig. 3k).  
A similar recovery was found when FSTL1-loaded patches were grafted one week after 
ischemia/reperfusion injury in the mouse, when cardiac function had substantially decreased 
(about 15% reduction in FS%). As is typical, cardiac function of untreated animals progressively 
declined (22%, 20% and 16% FS at 1, 3 and 5 weeks post-I/R). In contrast, the patch+FSTL1 
cohort showed a nearly complete and stable recovery of FS (to 34% three weeks post-I/R) 
(Extended Data Fig. 4a-d and Extended Data Table 2), suggesting that epicardial-delivered 
FSTL1 is sufficient to revert the loss of cardiac function after experimental MI. 
FSTL1 induces cardiomyocyte cell cycle entry in vivo 
Four weeks following MI, the patch+FSTL1 cohort showed evidence of striated myocytes (α-
actinin+ cells) within the patch (Extended Data Fig. 5a-d). Cardiomyocytes in the border zone had 
undergone cell division (Extended Data Fig. 5e-h) by several independent criteria, including an 
increased number of double-positive α-actinin+, phospho-Histone H3 (pH3)+ cells (Fig. 3j-I; and 
Extended Data Fig. 5e-h, i-k), increased incidence of Aurora B kinase localized to the midbody 
between α-actinin+ cells (Fig. 3m-n and Suppl. Video 6), and increased incidence of cells that 
were double-positive for pH3 and the nuclear cardiomyocyte maker PCM116 (Fig. 3o, p) relative 
to MI and patch-only cohorts (Extended Data Fig. 5l-r).  Thus, epicardial FSTL1 delivery 
activates cardiomyocyte cell cycle entry and cytokinesis in vivo reminiscent of the in vitro results 
above. Proliferating cardiomyocytes were found in the border zone and, to a lesser extent, the 
infarcted area, but not remotely in the myocardium (Extended Data Fig. 5s, t). Increased 
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cardiomyocyte proliferation was also observed in the I/R injury model with delayed patch 
implantation (Extended Data Fig. 4e, f). Notably, FSTL1 did not diminish cardiomyocyte 
apoptosis, the extent of the infarcted area or the area at risk (hypoperfused area) acutely after MI; 
nor did it affect apoptosis or inflammation at day 4 and day 8 post-MI (Extended Data Fig. 6).  
In contrast to patch+FSTL1 delivery, transgenic overexpression of Fstl1 (Fstl1-TG mice) did not 
show any evidence of cardiomyocyte proliferation after MI (Extended Data Fig. 2k,l), despite 
increased vascularization described previously13 (Extended Data Fig. 2m,n), indicating that 
epicardial-delivered FSTL1 might function differently than myocardial-expressed Fstl1.  
To distinguish whether the FSTL1-responsive cells arise from pre-existing myocytes (Myh6+ cells) 
or de novo from a progenitor population, we heritably labeled Myh6+ cardiomyocytes using a 4-
OH-tamoxifen-inducible Cre17 prior to injury (Fig. 3q). 4-OH tamoxifen injected into Myh6mERCremER: 
Rosa26Z/EG mice17 efficiently labeled pre-existing cardiomyocytes with eGFP prior to MI (Fig. 3r).  
Four weeks after patch engraftment, eGFP+, pH3+ double-positive cells were visible in the infarct 
area and border zone (Fig. 3s-v), indicating that the proliferating cardiomyocytes expressed Myh6 
prior to MI. We treated cardiomyocytes at different stages of differentiation with FSTL1 in order to 
determine which stage(s) can respond by proliferating.  Neither adult mouse cardiomyocytes 
(Extended Data Fig. 7a-f), neonatal rat cardiomyocytes (Extended Data Fig. 7g-j) nor 
cardiomyogenic progenitor cells (Lin-, Sca1+, SP+)18 responded (Extended Data Fig. 7k-m). Of 
the cells tested, only immature cardiomyocytes (mCMsESC) proliferated in response to FSTL1 
(Fig. 4a-f).  
It remained paradoxical that neither the endogenous Fstl1 induced by MI nor myocardially over-
expressed Fstl1 could induce a regenerative response (Fig. 3, Extended Data Fig. 2). Western-
blot analysis indicated that myocardially overexpressed Fstl1 (in neonatal rat ventricular 
myocytes, NRVC) migrates substantially slower in SDS-polyacryamide gels than does epicardial-
synthesized Fstl1 (EMC), and that tunicamycin treatment eliminates the difference (Fig. 4g), 
suggesting cell-type specific glycosylation.  The bacterially produced recombinant human FSTL1 
(as used in the patch) showed a faster migration consistent with less extensive glycosylation (Fig. 
4h, i).  Direct comparison of recombinant human FSTL1 produced in bacterial versus mammalian 
cells (NS0-derived mouse myeloma cell line) revealed that mammalian-expressed FSTL1, but not 
bacterial FSTL1, protects mCMsESC from H2O2-induced apoptosis (Fig. 4j), consistent with 
evidence of cardioprotection14 but not regeneration (Extended Data Fig. 2a-j) in Fstl1 TG mice.  
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In contrast, bacterially synthesized human FSTL1 promotes mCMsESC proliferation, whereas 
human FSTL1 produced in NS0-derived cells or NRVCs cannot stimulate proliferation of 
mCMsESC (Fig. 4k, l, m, n). Thus, whether FSTL1 induces cardioprotection versus proliferation 
correlates with cell source and might reflect post-translational modification. 
Epicardial FSTL1 in a preclinical swine model. 
Epicardial delivery of FSTL1 was evaluated in the swine model of I/R injury. I/R decreased left 
ventricular EF from ~50% prior to MI, as determined by magnetic resonance imaging (MRI), to 
~30% at 1 week after injury.  Application of the patch+FSTL1 to the epicardium over the injured 
tissue at this time stimulated recovery of contractile function (to ~40% EF) in 2 weeks (3 weeks 
post-MI I/R) (Fig. 5a, b). The recovery remained stable for an additional 2 weeks, the longest time 
analyzed, and was in contrast to the steady decline seen without treatment or following treatment 
with patch alone (Fig. 5b). FSTL1-treated pigs demonstrated the least scar size of all treatments, 
including the patch-only condition [see representative MRI images (Fig. 5c, d)]. Examination of 
histological sections of tissues 4 weeks after patch implantation confirmed the limited fibrosis and 
showed integration of the patch into the host tissue (Fig. 5e). Cardiomyocytes in the border zone 
and ischemic area of the Patch+FSTL1 treated hearts also had evident EdU labeling (Fig. 5i-m) 
and midbody-localized Aurora B kinase (indicative of cytokinesis) (Fig. 5n). Vascular smooth 
muscle cells were also EdU+ suggestive of arteriogenesis (Fig. 5g, h). Thus, the patch+FSTL1 
appears therapeutic in the swine MI I/R model.  
Discussion 
Heart regeneration studies in zebrafish suggested that the epicardium is activated by injury to 
produce factors and cells that sustain cardiac function19.  Unlike lower vertebrate hearts, which 
are robustly regenerative, the mammalian heart retains negligible regenerative potency in 
adulthood and, instead, sustains cardiomyocyte death and scarring following injury.  Very little is 
known of the endogenous mechanisms that limit regeneration and the topic remains a subject of 
intense therapeutic interest and scientific debate20. Our data suggest a new view of epicardial 
function after injury in the mammalian heart.  Rather than activation to support cardiac function, 
the loss of epicardial FSTL1 expression after injury, and the functional and anatomical recovery 
by reconstitution in an engineered biomaterial, indicate that ischemic injury induces a maladaptive 
loss of FSTL1 in the epicardium.   
Wei, Serpooshan et al.              Engineered Epicardium Activates Cardiac Regeneration               Page 8  
 
We sought to identify the cell population that proliferates in response to FSTL1. FSTL1 could not 
stimulate mature adult ventricular cardiomyocytes to synthesize DNA or divide, nor did it induce 
hypertrophy (as can occur in response to mitogens) either at 48 hours (Fig. 2g) or 4 weeks post-
MI (Ext Fig. 5o). In contrast, FSTL1 stimulated replication of newly emerging cardiomyocytes 
from mouse ESC cultures (Fig. 4a-f).  FSTL1 did not enhance replication of either ESC-derived 
progenitors prior to the appearance of Myh6 (not shown) or a population of cardiac progenitors 
isolated from the adult murine heart (Extended Data Fig. 7k-m), suggesting that competence to 
respond to FSTL1 occurs transiently.  Although at least some mononuclear adult cardiomyocytes 
can be induced to divide21, the FSTL1-responsive cardiomyocytes in our experiments have even 
less mature sarcomeric and electrophysiological properties22 (e.g. automaticity, relatively high 
maximum diastolic potential, and slow action potential peak Vmax) (Extended Data Fig. 1). The 
cells that respond to FSTL1 might overlap cells identified in an earlier analysis of infarcted hearts 
labeled with Myh6-Cre, in which a minor population of Cre-labeled cells were reported to divide 
and give rise new cardiomyocytes upon ischemic injury23.  Whether the FSTL1-responsive cells 
reflect resident Myh6+ recruited upon injury e.g.23 or derive from de-differentiation24 (thus 
recapitulating the Zebrafish model25) is an interesting question whose resolution will depend on 
improved method to identify and/or isolate such cells.  
Myocardial Fstl1 induced by MI cannot promote a regenerative response, either basally or when 
abundantly overexpressed transgenically in cardiomyocytes (Extended Data Fig. 2). However, 
transgenic myocardial Fstl1 is cardioprotective post-MI14.  Direct comparison of Fstl1 
overexpressed in cardiomyocytes versus the epicardial (EMC) protein revealed tunicamycin-
sensitive differences in SDS-PAGE mobility (Fig. 4), consistent with the possibility of differential 
glycosylation (or other post-translational modification) depending on the cell in which it is 
expressed. We infer from these data that native epicardial and myocardial FSTL1 have analogous 
differences in glycan structure that affect their function. It will be important to determine the 
structure of the glycans, as well as elucidate how post-translation modifications dictate whether 
FSTL1 promotes anti-apoptosis (myocardial) or cardiomyocyte proliferation (EMC and bacterially 
produced).  
These studies identified FSTL1 as a regenerative factor that is normally present in healthy 
epicardium, but lost upon MI suggesting a mechanism whereby injury maladaptively diminishes 
the regenerative potency of the mammalian heart.  Reconstitution of FSTL1 by an engineered 
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epicardial biomaterial improved cardiac function in the mouse MI, mouse MI I/R and preclinical 
swine MI I/R models with evidence of cardiomyocyte regeneration amenable to clinical translation. 
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Figure Legends  
 
Figure 1. Epicardial secretome contain cardiogenic activity, and improves cardiac function 
after MI via embryonic epicardium-like patches 
a-d) Co-culture of mCMsESC cardiomyocytes with epicardial EMC cells. Representative 
micrographs (a,b). Quantification of myocyte number (c) and cardiac gene expression (d). *: 
p<0.05 compared to acellular (EMC-) control; ■ p<0.05 compared to 1X105 cells condition. 
e-i) Culture of  mCMsESC  cardiomyocytes with EMC-conditioned media.  Representative 
micrographs (e,f). Quantification of myocyte number (g), cardiac gene expression (h), and 
cardiomyocytes with rhythmic calcium transients (i). *: p<0.05 compared to control. 
j-m) Effect of adult epicardial media on embryonic cardiomyocytes from E12.5 GFP+ cells 
(Tnnt2-Cre;Rosa26mTmG/+) (j). Conditioned media obtained from adult epicardial-derived cells 
(EPDCs) promotes cardiomyocyte proliferation that can be heat-inactivated (k) and cytokinesis 
analyzed by double immunostaining for Aurora B and Tnnt2  (cardiomyocytes) (l, m). *: p < 0.05 
n) Cartoon of collagen patch generation (reconstructed from 26). 
o) Evaluation of mechanical properties of engineered patch, measured by atomic force 
microscopy.  
p-q)  Suture procedure of patch over ischemic myocardium. 
r) Echocardiography analysis normalized to individual pre-surgery baseline values, s) absolute 
values of fractional shortening (FS%), and t) Masson’s trichrome staining of the animal cohorts: 
sham (control, n=10), infarcted mice without treatment (MI-only, n=8), MI treated with patch-only 
(MI+Patch, n=8), and infarcted animals treated with patch laden with epicardial conditioned media 
(MI+Patch+CM, n=8), 2 weeks after MI. *: p<0.05 compared to Sham control, ●: p<0.05 compared 
to MI-only, and ■: p<0.05 compared to MI+Patch. (See Methods for details.) 
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Figure 2. Fstl1 is an epicardial cardiogenic factor with dynamic expression after ischemic 
injury. 
a) MS/MS spectrum of Fstl1. 
b-g) Fstl1 treatment of mCMsESC cardiomyocytes measured by:) immunostaining (α-actinin, 
green) (b,c), quantification of myocyte number (d), expression of cardiac-specific markers (e), 
cardiomyocytes with rhythmic calcium transient (f), and individual cardiomyocyte cell size (g) *: 
statistically significantly different from control (p<0.05).  
h) Fstl1 immunostaining in the mouse embryonic heart (days E12.5, E15.5 and E17.5). Fstl1 
(red), Wt1 (epicardial marker), α-actinin (myocardial marker), DAPI (nuclei). Fstl1 is expressed in 
epicardium (white arrowheads), no myocardium (yellow arrowheads). 
 i) Expression shift of Fstl1 in the mouse heart after MI. Trichrome staining (upper), labels fibrosis 
(blue) Fstl1 immunohistochemistry (lower panels, brown). Observe that in injured hearts Fstl1 
expression is depleted from the epicardium (brown) and upregulated in the myocardium.  
j-l) High resolution images of Fstl1 expression-shift after MI (see Methods for details). 
 
Figure 3.  FSTL1 recapitulates the in vivo restorative effect of epicardial conditioned-media 
in the engineered epicardial patch, and promotes cardiomyocyte proliferation. 
 
 a-b) Survival (a) and Kinetics of FS(%) (b) analyses after MI in the indicated treatments. 
c) Effect of epicardial hFSTL1 patches on FS% in Fstl1-TG mice.  
 d-i) Masson’s trichrome staining (d), morphometric analysis by echocardiography (e), and 
vascularization analysis (f-i) 4 weeks after MI. *: p<0.05 compared to sham, ●: p<0.05 vs MI-only, 
and ■: p<0.05 vs MI+Patch.  
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j) Cross-sections covering infarct/patch area separated 250μm, 1-2mm from apex used for 
cardiomyocytes proliferation analysis (k-p), 4 weeks aft er MI.  
k, m, o) Co-staining of pH3 and α-actinin (k), midbody-localized Aurora B kinase between α-
actinin+ cells (m), and ouble-positive cells for pH3 and PCM1 (cardiomyocyte nuclei16) (o) 4 
weeks post-MI, quantified in (l, n, p) normalized to myocardium area quantified by trichrome 
staining of immediate adjacent section. *: P<0.05 from sham. **: P<0.05 from all other groups.  
q-v) Lineage tracing of FSTL1-responsive cells in 4-OH-tamoxifen treated 
Myh6mERCremER:Rosa26Z/EG mice; patch+FSTL1 applied simultaneously to MI, and hearts were 
collected 4 weeks post-MI (q) with efficient labeling of cardiomyocytes (r). Infarcted hearts 
showing eGFP+ (pre-existing, green) cardiomyocytes positive for pH3 (yellow arrowheads) (white 
arrowheads: pH3+ eGFP- cells) (s-v). (length of treatment (a-c) and n for each experiment 
indicated in graph, see Methods for details) 
 
Figure 4. FSTL1 proliferative activity on early cardiomyocytes depends on cells- selective 
post-transcriptional FSTL1 modifications. 
a-f) FSTL1 promotes proliferation of mCMsESC, measured by EdU incorporation (a), pH3 (b), and 
Aurora B immunostaining (c), and quantified in d-f. 
 g-i) Western blot analysis of Fstl1 secreted in cultured cardiomyocytes (myoFSTL1 CM) infected 
with Adeno-Fstl1 and in EMC (EMC CM) in the presence of tunicamycin (glycosylation inhibitor) 
(g), hFSTL1-V5 tagged expressed in AD-293 cells (h), and mammalian and bacterial-produced 
FSTL1 (i). Arrows: red: glycosylated; black: hypoglycosylated.  
j) Mammalian-produced FSTL1 attenuates H2O2 induced apoptosis, while bacterial-produced 
FSTL1 cannot.  
K, l) Bacterially-produced FSTL1 promotes mCMsESC EdU incorporation and Aurora B positivity 
whereas mammalian-produced FSTL1 does not. 
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m, n) Quantification of EdU incorporation in mCMsESC treated with conditioned media of EMC and 
Fstl1-overexpressing NRVC (concentration normalized to Fstl1 content).  
*: statistically different from control, P<0.05. (see Methods for details) 
o) Working model of FSTL1 in distinct cardiac compartments.  
 
Figure 5. Epicardial FSTL1 delivery activates cardiac regeneration in preclinical model of 
ischemic heart injury. 
 
a-d) Time course MRI analysis of cardiac function in pigs. Functional analysis by measure of 
election fraction (EF%) (a,b). Scar size at week-4 post-grafting (c,d). Green lines highlight scar 
perimeter.  
e-n) Analysis at week 4 post-grafting. Masson’s trichrome staining (e). EdU incorporation (newly 
synthesized DNA) in the vascular smooth muscle cells (f-h). White line demarcates patch and 
host tissue. i-m) EdU incorporation  and n) Aurora B kinase positivity in cardiomyocytes at week-4 
post-grafting. (See Methods for details.) 
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Methods 
 
Cell Preparation: 
Progenitor cells Sca1+,Myh6
-
 cardiomyocyte progenitors were obtained by the Schneider 
laboratory  as described 18 (Extended Data Fig. 7 k-m).   
Epicardial Mesothelial Cells (EMCs) were maintained in DMEM with 10% FBS and 
antibiotics/antimycotic as described 27. EMCs are stably transduced with H2B-mCherry Lentivirus 
for nuclei labeling (Fig. 1, 4). 
Mouse embryonic stem cell-derived cardiomyocytes (mCMsESC ):  A stable mouse ESC line for 
drug resistance selection of cardiomyocytes (Myh6-Puror;Rex-Blastr) was generated by lentiviral 
transduction and blasticidin selection, similarly to our previously reported human line 28 
mCMsESC were obtained by differentiation of  Myh6-Puror;Rex-Blastr mESCs in a differentiation 
media containing: Iscove’s Modified Dulbecco Media (IMDM) supplemented with 10% FBS, 2mM 
glutamine, 4.5x10-4 M monothioglycerol, 0.5 mM ascorbic acid, 200 µg/mL transferrin (Roche), 5% 
protein-free hybridoma media (PFHM-II, Invitrogen) and antibiotics/antimycotic as embryoid 
bodies (EBs) until day 4 and plated onto adherent cell culture plate until 9,  one day after the 
onset of spontaneous beating. To purify Myh6+ cardiomyocytes, puromycin was added at 
differentiation day 9 for 24 hours. Subsequently cells were trypsinized and plated as monolayer 
cardiomyocytes.  Conditioned media and FSTL1 treatments were typically performed 24 hours 
after monolayer plating. The length of the treatments is indicated in each figure legends (Fig. 1, 2, 
4, Extended Data Fig. 1). 
AD-293 cells were directly purchased from Stratagene avoiding misidentification, and cultured in 
DMEM media with 10% FBS and with pen/strep. It’s used for its high transfection efficiency and 
yield of recombinant proteins (Fig. 4h). 
EMCs and Myh6-Puror;Rex-Blastr mESCs, and AD-293 cells are quarterly tested for mycoplasma 
contamination when in use. 
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Embryonic cardiomyocytes. We used fluorescence activated cell sorting (FACS) to purify 
cardiomyocytes from Tnt-Cre;Rosa26mTmG/+ (C57BL/6J and ICR mixed background) hearts from 
e12.5 embryos.  Hearts were dissociated collagenase IV digestion and GFP+ cells for FACS 
purification.  The GFP+ cells were cultured and confirmed to be cardiomyocytes by their 
expression of the cardiomyocyte specific markers alpha actinin (ACTN2) and cardiac troponin T 
(TNNT2).  They were rhythmically beating when cultured in vitro (Fig. 1j-m). 
Neonatal rat ventricular cardiomyocytes (NRVCs) were isolated with the neonatal rat 
cardiomyocyte isolation kit (Cellutron) and cultured at 37°C with 5% CO2. In brief, ventricles were 
dissected from 1–2-d-old Hsd:SD rats (Sprague Dawley), then digested five times for 15 minutes 
each with the enzyme cocktail at 37°C.  Cells were pooled, pre-plated for 90 minutes on an 
uncoated cell culture dish to remove fibroblasts, and plated on 1% gelatin-coated cell culture 
plastic dishes in high-serum media (DME/F12 [1:1], 0.2% BSA, 3 mM sodium-pyruvate, 0.1 mM 
ascorbic acid, 4 mg/liter transferrin, 2 mM L-glutamine, and 5 mg/liter ciprofloxacin supplemented 
with 10% horse serum and 5% fetal bovine serum (FBS)) at 3 × 105 cells/cm2. After 24 hours, 
media was changed to low-serum medium (same but with 0.25% FCS) and cells cultured until use 
(Fig. 4g, m, n, Extended Data Fig. 7g-j). 
Adult mouse cardiomyocytes were isolated from 3 mo old Myh6mERCremER:Rosa26Z/EG. C57BL/6J 
mice as previously published29. Briefly, mice were anesthetized with pentobarbital sodium (100 
mg/kg IP). The heart was removed and retrograde perfused at 37oC with a Ca2+ free solution (in 
mM, 120 NaCl, 14.7 KCl, 0.6 KH2PO4, 0.6 Na2HPO4, 1.2 MgSO4-7H2O, 4.6 NaHCO3, 10 Na-
HEPES, 30 taurine, 10 BDM, 5.5 glucose) followed by enzymatic digestion with collagenase. 
Ventricles were cut into small pieces and further digested. Stop buffer (Ca2+ free solution + CaCl2 
12.5 μM + 10% bovine calf serum) was added and the cell suspension was centrifuged at 40g for 
3 min. Myocytes were resuspended in stop buffer in increasing CaCl2 concentrations until 1mM 
was achieved. Cells were then resuspended in MEM + 5% bovine calf serum + 10mM BDM + 
2mM L-Glutamine and added to the collagen solution, pre-polymerization (250,000 cells per ml or 
per patch). Following collagen gelation and plastic compression, cellular patches were cultured in 
aforementioned (plating) media overnight and then transferred into culture media: MEM + 1mg/ml 
bovine serum albumin + 25 µM blebbistatin + 2mM L-Glutamine, in presence or absence of 
recombinant FSTL1 (AVISCERA BIOSCIENCE, 10 ng/ml). At day 7, fluorescent ubiquitination-
based cell-cycle indicator (FUCCI, Premo™ FUCCI Cell Cycle Sensor, Life Technologies, US) 
assay was conducted on the 3D culture specimens as previously described30. In this assay, G1 
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and S/G2/M cells emit red and green fluorescence, respectively. The volume of Premo™ geminin-
GFP and Premo™ Cdt1-RFP were calculated using the equation below: 
Volume	of	Premo™	geminin	GFP	or	Premo™	Cdt1	RFP	reagent	ሺmLሻ = 	number	of	cells × PPC1	 × 	10଼  
where the number of cells is the estimated total number of cells at the time of cell labeling (equal 
to CM seeding density, PPC (particles per cell) is the number of viral particles per cell (=40 in this 
assay), and 1 ×108 is the number of viral particles per mL of the reagent. The volumes of reagents 
calculated above were directly added to the cellular patches in complete cell medium, mixed 
gently, and incubated overnight in the culture incubator (≥16 hrs). Patch samples were imaged 
using a conventional fluorescence microscope, utilizing GFP and RFP filter sets (Extended Data 
Fig. 7a-f).  
 
Co-culture experiments 
mCMsESC are co-cultured with H2B-mCherry EMCs for 4 days and visualized by α-actinin 
immunofluorescent staining and H2B-mCherry fluorescence (Fig. 1a, b), cardiomyocyte counting 
(Fig. 1c, n=3), and cardiogenic gene expression normalized to Gapdh gene expression (Fig. 1d 
n=3) 
Epicardial conditioned media:  
 
Rat epicardial mesothelial cells (EMC) conditioned media. EMC 27 cells were cultured in 10% FBS 
DMEM with pen/strep until confluent (~1X106/cm2), then washed with PBS 3 times and media is 
changed to serum free DMEM with pen/strep without phenol red and cultured for 2 additional days 
before the media was collected as conditioned media (20ml of media is added for conditioning 
and 18ml is collected after 2 days). Collected media was filtered through 0.22um pore membrane 
(Millipore). Control conditioned media were prepared the same way but without EMC cells (Fig. 
1e-I, n-t).  
Neonatal rat ventricular cardiomyocytes (NRVCs) conditioned media. NRVC were infected with 
adenovirus expressing un-tagged mouse Fstl1 at MOI 50. 24 hrs post-infection culture media was 
replaced by serum free media (DMEM/F12 with pen/strep). The media was conditioned with the 
infected NRVC and EMC cells for 24 hrs (Fig. 4m, n). 
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mCMsESC were treated with control and EMC-conditioned media for 8 days before α-actinin 
immunofluorescent staining (Fig. 1e, f), cardiomyocyte counting (Fig. 1g, n=3), analysis of 
cardiogenic gene expression normalized to Gapdh gene expression (Fig. 1h n=3) and 
quantification of the number of cardiomyocytes with rhythmic calcium transient measured 
automatically using a Kinetic Imaging Cytometer (Vala Sciences) (Fig. 1i, n=3). 
mCMsESC were treated with serial dilutions of conditioned media of EMC and Fstl1-overexpressing 
NRVC for 24 hours with 10μg/ml EdU, and stained for α-actinin and EdU (Fig. 4m, n, n=5). The 
concentrations of the conditioned media are normalized to amount of Fstl1 expression by western 
blot. 
Adult mouse EPDC conditioned media was generated in the Zhou laboratory8.  Briefly, eight-week 
old adult Wt1CreERT2/+;Rosa26mTmG/+ hearts mice in C57BL/6J and ICR mixed background were 
injected orally 4 mg tamoxifen by gavage, four to five oral injections were administered during a 
two-week period. Myocardial infarction was then induced by ligation of left anterior descending 
coronary artery on (11 weeks old) adult mice. One week after injury, we collected 
Wt1CreERT2/+;Rosa26mTmG/+ hearts, which were then digested with collagenase IV into single cells. 
Digestion solution was made by adding 4ml 1% collagenase IV and 1ml 2.5% trypsin into 44.5 ml 
Hanks’ Balanced salt solution, and supplemented with 0.5 ml chicken serum and 0.5 ml horse 
serum. Cells were re-suspended in Hank’s balanced salt solution, 4ml digestion solution was 
added to each tube and rocked gently in 37°C shaker for 6 minutes. After removing the 
supernatant containing dissociated cells, we added another 4ml digestion solution to repeat the 
digestion 6 times. After final digestion, we filtrated the cells through 70 µm filter and pellet cells by 
centrifuging at 200g for 5 minutes at 4°C. Cells were then re-suspended by Hanks’ balanced salt 
solution for FACS isolation. Dissociated cells from GFP- hearts were used as a control for gate 
setting in FACS. GFP+ cells (epicardium-derived cells, EPDCs) were isolated from 
GFP+ Wt1CreERT2/+;Rosa26mTmG/+ hearts by FACS and these GFP+ purified populations were 
confirmed to be GFP+ cells under fluorescence microscope (Fig. 1j). FSTL1 expression 
(determined by PCR) was restored in cultured GFP+ EDPCs.  Complete conditioned media from 
EPDCs was then added to embryonic cardiomyocytes culture for 48 hours before assay for 
proliferation  (Fig.1k-m, n=5).  
MTT Assays. Proliferation of cardiomyocytes treated with conditional medium was measured by 
MTT assay using Celltiter 96 Aqueous One solution (Promega) as previously described8. After 
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adding the Celltiter 96 Aqueous One reagent into the cell culture medium, we incubate the plate at 
37°C for 3-4 hours, and then record the absorbance at 490nm using a 96-well plate reader. 
Absorbance at 490nm is tightly correlated with cell number. The MTT readout on the y-axis, 
labeled MTT assay (A490), thus reflects the relative number of cells from each well between 
groups of treatment (Fig.1 k). Boiling of conditioned media abolished the growth-promoting effects 
(Fig.1 k), suggesting a proteinaceous nature of the effective components. 
Recombinant FSTL1 was purchased from AVISCERA BIOSCIENCE (00347-02-100, produced in 
E. Coli) and R&D system (1694-FN-050 , produced in mouse myeloma cell line, NS0-derived ).   
mCMsESC were treated with bacteria-synthetized recombinant human FSTL1 (10 ng/ml) for 8 days 
with media change every 2 days, before α-actinin immunofluorescent staining (Fig. 2b, c), 
cardiomyocyte counting (Fig. 2d, n=8), analysis of cardiogenic gene expression normalized to 
Gapdh gene expression (Fig. 2e, n=3) and quantification of the number of cardiomyocytes with 
rhythmic calcium transient measured automatically using a Kinetic Imaging Cytometer (Vala 
Sciences) (Fig. 2f, n=6). mCMsESC were treated with bacteria-synthetized recombinant human 
FSTL1 (6.25-50 ng/ml) for 2 days before measurement of individual cardiomyocyte cell size (in 
pixels) (Fig. 2g, n=5).   
mCMsESC were stimulated with 6.25, 12.5, 25 and 50ng/ml of bacteria produced FSTL1 for 24 
hours with 10μg/ml EdU, and stained for α-actinin and EdU (Fig. 4a, d, n=5). mCMsESC were 
stimulated with 10ng/ml FSTL1 for 48 hours and stained for α-actinin and pH3 (Fig. 4b, e, n=5). 
mCMsESC were stimulated with 25, 100, 200ng/ml FSTL1 for 48 hours, and stained for α-actinin 
(red) and Aurora B (Fig. 4c, f, n=5) 
mCMsESC were stimulated with 10nM H2O2, and 10ng/ml bacteria and mammalian produced 
FSTL1 for 24 hours, and staining for α-actinin and TUNEL for cell death (Fig. 4j, n=5). 
mCMsESC were stimulated with 10ng/ml of bacteria and mammalian produced FSTL1 for 24 hours 
with 10μg/ml EdU, and stained for α-actinin and EdU (Fig. 4k, n=5) , and  α-actinin and Aurora B 
(Fig. 4l, n=5) 
FSTL1 overexpression and western blot  AD-293 cells were transiently transfected with human 
FSTL1 plasmid (GE Dharmacon, ID: ccsbBroad304_02639 pLX304-Blast-V5-FSTL1) using 
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lipofectamine 2000 (mocked transfection was done with lipofectamine and no plasmid). 48 hrs 
post-transfection serum containing media was replaced by serum free DMEM and incubated with 
the cells for 24 hrs. Tunicamycin was used at 2 μg/ml. Conditioned media from tunicamycin 
samples was collected during 16 hrs (cells looked healthy). Conditioned media was spun at 400g 
7 min and then concentrated approximately 20 times using Microcon-10 kDa cut off columns 
(Millipore).  Samples were combined 1 to 1 ratio with 2x SDS sample buffer containing protease 
inhibitor, DTT and 5mM EDTA, boiled 10 minutes at 95C and run in a 4-15% acrylamide Mini-
Protean TGX gel, transferred to nitrocellulose membrane and incubated with anti-V5 primary 
antibody MAB 15253 (Pierce) 1:1,000 dilution and anti-mouse 800 nm conjugated secondary 
antibody at 1:10,000 dilution (Odyssey), and scanned using Odyssey Clx Imager (Fig. 4h).  
Neonatal rat ventricular cardiomyocytes were infected with adenovirus expressing un-tagged 
mouse Fstl1 at MOI 50. 24 hrs post-infection culture media was replaced by serum free media. 
Serum free DMEM/F12 pen/strep media was conditioned with the infected NRVC and EMC cells 
for 24 hrs. Tunicamycin was used at 1ug/ml and media was conditioned for 16 hrs.  Conditioned 
media was spun at 400g 7 minutes and then concentrated using Microcon-10 kDa cut off columns 
(Millipore).  Samples were combined 1 to 1 ratio with 2x SDS sample buffer containing protease 
inhibitor, DTT and 5mM EDTA, boiled 10 minutes at 95C and run in Any KD Mini-Protean TGX 
gel, transferred to nitrocellulose membrane and incubated with anti-FSTL1 MAB1694 (R&D) 
primary antibody 1:500 dilution and anti-rat 800 nm conjugated secondary antibody at 1:10,000 
dilution (Odyssey), and scanned using Odyssey Clx Imager. Blocking and antibody incubation 
was done in Odyssey blocker. The western blot for recombinant FSTL1 (100ng each) was 
performed the same way (Fig. 4g, i).  
RNA extraction and Q-RT-PCR . Total RNA was extracted with TRIzol (Invitrogen) and reverse 
transcribed to cDNA with QuantiTect Reverse Transcription Kit (Qiagen) according to the 
manufacturer’s instructions.  cDNA samples synthesized from 100ng of total RNA were subjected 
to RT-QPCR with LightCycler 480 SYBR Green I Master kit (Roche) performed with LightCycler 
480 Real-Time PCR System (Roche) (Fig. 1d, h, 2e, Extended Data Fig. b-d). Primer 
sequences are listed in Supplementary Table: 
LC-MS/MS analysis of conditioned-media.  First, Tris(2-carboxyethyl)phosphine (TCEP) was 
added into 1 mL of conditional media to 10mM and the protein sample was reduced at 37°C for 
30 min. Then iodoacetamide was added to 20mM and the solution was alkylated at 37°C for 40 
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min in the dark.  Mass Spectrometry Grade of trypsin (Promega) was then added to the solution 
as 1:100 ratio. After overnight digestion at 37°C, the sample was then desalted using a SepPack 
cartridge, dried using a SpeedVac and re-suspended in 100 µL of 5% formic acid. The resulting 
peptides were analyzed on-line by an LC-MSMS system, which consisted of a Michrom HPLC, a 
15 cm Michrom Magic C18 column, a low flow ADVANCED Michrom MS source, and a LTQ-
Orbitrap XL (Thermo Scientific, Waltham, MA). A 120-min gradient of 0-30%B (0.1% formic acid, 
100% acetonitrile) was used to separate the peptides, and the total LC time was 141 min. The 
LTQ-Orbitrap XL was set to scan the precursors in the Orbitrap at a resolution of 60,000, followed 
by data-dependent MS/MS of the top 4 precursors.  
The raw LC-MSMS data was then submitted to Sorcerer Enterprise (Sage-N Research Inc.) for 
protein identification against the IPI rat protein database, which contains semi-tryptic peptide 
sequences with the allowance of up to 2 missed cleavages and precursor mass tolerance of 50.0 
ppm. A molecular mass of 57 Da was added to all cysteines to account for 
carboxyamidomethylation.  Differential search includes 16 Da for methionine oxidation. The 
search results were viewed, sorted, filtered, and statically analyzed using PeptideProphet and 
ProteinProphet (ISB). The minimum trans-proteomic pipeline (TPP) probability score for proteins 
and peptides was set to 0.95, respectively, to assure TPP error rate of lower than 0.01. The 
example MS/MS spectrum R.GLCVDALIELSDENADWK.L was identified as Fstl1 (Fig. 2a). 
Peptide probability=1.0, Xcorr=6.276, delta Cn=0.471. 
Automated in vitro cell proliferation and cell death assay:. Cells (mCMsESC and NRVC) were 
incubated with EdU (details of dosage and length of exposure are specified in figure legends) in a 
384 wells plate format, and were fixed for 2 hours in 4% PFA, washed in PBS and stained for EdU 
using Click-it EdU assay kit (Life Technologies). The cells were then washed in PBS, 
immunostained with an α-actinin antibody (Sigma, A7811, 1:500) to identify cardiomyocytes and 
stained with DAPI (4',6-diamidino-2-phenylindole, 1:10,000) to identify nuclei. The plates were 
then imaged using InCell 1000 system (GE Healthcare) and automatically analyzed in Developer 
Toolbox (GE Healthcare) as described 31. Ratios of EdU+/ α-actinin+ nuclei and α-actinin+ nuclei 
were generated for the percentage of cardiomyocyte incorporated EdU in the chromosomal DNA. 
Similarly, cells (mCMsESC and NRVC) in 384 wells plate format were fixed for 2 hours in 4% PFA, 
washed in PBS, and were immunostained with pH3 antibody (Millipore 06-570, 1:200) for nuclei in 
mitosis, or Aurora B (Millipore 04-1036, 1:200) for cytokinesis, or TUNEL (Roche) for cell death, 
and α-actinin antibody (Sigma, A7811, 1:500) for cardiomyocytes and DAPI (1:10,000) for nuclei. 
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The same imaging and analysis were done for pH3 staining as the EdU assays, and the Aurora 
B+,  α-actinin+ double positive cells were manually counted. The percentages of pH3+, α-actinin+ 
double positive nuclei, Aurora B+,  α-actinin+ double positive cells, and TUNEL+, α-actinin+ double 
positive nuclei relative to the total number of α-actinin+ cell nuclei were calculated to determine 
the percentages of cardiomyocytes undergoing mitosis, cytokinesis and apoptosis, 
respectively.Calcium Imaging. Contractile calcium transients were recorded using a Kinetic Image 
Cytometer (KIC, Vala Sciences) using Fluo4 NW calcium indicator (Life Science). Data was 
processed using Cyteseer software containing the KIC analysis package (Vala Sciences) as 
described 32. 
Compressed collagen gel for use as an engineered epicardial patch. Highly hydrated 
collagen gels – used as cardiac patch in this study – were produced by adding 1.1 ml 1X DMEM 
(Sigma, MO, US) to 0.9 ml of sterile rat tail type I collagen solution in acetic acid (3.84 mg/ml, 
Millipore, MA, US). The resulting 2 ml collagen-DMEM mixture was mixed well and neutralized 
with 0.1 M NaOH (~50 µl). The entire process was conducted on ice to avoid premature gelation 
of collagen. In the case of patches containing epicardial factors, the EMC culture media was 
collected as above and 0.6 ml of that was mixed with 0.5 ml DMEM. The collagen solution (0.9 ml) 
was then distributed into the wells of 24-well plates (15.6 mm in diameter) and placed in a tissue 
culture incubator for 30 min at 37oC for polymerization. For pig studies, 6.8 ml of collagen was 
mixed with 8.2 ml DMEM to obtain a 15 ml solution that was then cast into a 6-cm Petri dish (A = 
28.3 cm2). Plastic compression was performed as described previously33,34. Briefly, as cast, highly 
hydrated collagen gels (at ~0.9 and 15 ml volumes for the mice and swine study, respectively) 
underwent unconfined compression via application of a static compressive stress of ~1,400 Pa for 
5 minutes (see33,35 for details), resulting in ~98-99% volume reduction (Fig. 1n). The elastic 
modulus of the compressed collagen, aimed to approximate that of the embryonic epicardium 
which is optimal for contractility of immature cardiomyocytes (see text36), was assessed by atomic 
force microscopy (AFM) in nano-indentation mode, using a force trigger that resulted in a minimal 
local strain of less than 10% (indentation of ~100 nm) to minimize the effect of substrate-related 
artifacts. A custom-made flat AFM tip was manufactured using focused ion beam milling and 
utilized to probe the stiffness of the gels by scanning areas of 90 µm × 90 µm. Histogram of the 
distribution of measured micro stiffness of the patch is compared with the range of elasticity 
reported for common scaffolding biomaterials37, and previously described36 optimal range of 
elasticity to maximize myocyte contractility (Fig. 1o, n=3). 
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Myocardial Infarction and application of the epicardial patch 
Permanent LAD occlusion (MI): Male 10-12 weeks old C57BL/6J mice were purchased from 
Jackson Laboratories (Bar Harbor, ME, USA). Fstl1-TG mice used in MI experiments are C57BL6 
background, female and male mice age 12-15 weeks old. Mice were anesthetized using an 
isoflurane inhalational chamber, endotracheally intubated using a 22-gauge angiocatheter 
(Becton, Dickinson Inc., Sandy, Utah) and connected to a small animal volume-control ventilator 
(Harvard Apparatus, Holliston, MA). A left thoracotomy was performed via the fourth intercostal 
space and the lungs retracted to expose the heart. After opening the pericardium, a 7-0 suture 
was placed to occlude the left anterior descending artery (LAD) ~2 mm below the edge of the left 
atrium. Ligation was considered successful when the LV wall turned pale (Fig. 1p). In the case of 
experimental groups treated with patch, immediately after the ligation, prepared collagen patch 
was sutured (at two points) onto the surface of ischemic myocardium (Fig. 1g). The patch size 
used was ~ one third of the 15.6 mm-diameter collagen gel. Animals were kept on a heating pad 
until they recovered. Another group of mice underwent sham ligation; they had a similar surgical 
procedure without LAD ligation. A minimum number of n=8 was used in each study group. 
 
Ischemia reperfusion (I/R).  Male C57/BL6, aged 10 to 11 weeks, were anesthetized and 
intubated as described above. A left lateral thoracotomy was then performed. Pericardium was 
gently pulled off and an 8-0 Nylon suture (Ethicon, Inc. Johnson & Johnson Co., USA) was used 
to ligate the left anterior descending coronary artery against a PE10 tubing, which was removed 
after 30 minutes occlusion. Successful performance of coronary artery occlusion was verified by 
visual inspection (by noting the development of a pale color in the distal myocardium upon 
ligation). The chest was then closed using 7-0 sutures around adjacent ribs, and the skin was 
closed with 6-0 suture. Buprenorphine was administered subcutaneously for a minimum of 1 day 
at BID dosing. For the animal group treated with patch, a second thoracotomy was performed one 
week post the incidence of I/R and the prepared collagen patch was sutured (at two points) onto 
the surface of ischemic myocardium. Sham-operated controls consisted of age-matched mice that 
underwent identical surgical procedures (two thoracotomies) with the exception of LAD ligation 
(Extended Data Fig. 4). 
Echocardiography. In vivo heart function was evaluated by echocardiography at 2 weeks (Fig. 
1r, s, Fig. 3b, c, Extended Data Fig. 2 h-j), 4 weeks (Fig. 3b, c, e, Extended Data Fig. 2 h-j), 
and 2 and 3 months (Fig. 3b) after LAD ligation. Two-dimensional (2D) analysis was performed 
on mice using a GE Vivid 7 ultrasound platform (GE Health Care, Milwaukee, WI) equipped with 
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13 MHz transducer. The mice were sedated with isoflurane (100 mg/kg, inhalation), and the chest 
was shaved. The mice were placed on a heated platform in the supine or left lateral decubitus 
position to facilitate echocardiography. 2D clips and M-mode images were recorded in a short axis 
view from the mid-left ventricle at the tips of the papillary muscles. LV internal diameter (LVID) 
and posterior wall thickness (LVPW) were measured both at end diastolic and systolic. Fractional 
shortening (FS, %) and ejection fraction (EF, %, via extrapolation of 2D data) were calculated 
from LV dimensions in the 2D short axis view. A minimum number (n) of 8 mice per experimental 
group was used for the echo evaluations. Measurements were performed by two independent 
groups in a blind manner. In ischemia reperfusion study, in vivo heart function was evaluated pre-
surgery (baseline), 1 week after the incidence of I/R, and two and four weeks post-implantation 
(Extended Data Fig. 4a-d). 
In vivo delayed-enhanced magnetic resonance imaging (DEMRI). To prepare for scanning, 
induction of anesthesia was accomplished with 2% and maintained with 1.25-1.5% isoflurane with 
monitoring of the respiratory rate.  ECG leads were inserted subcutaneously to monitor the heart 
rate while the body temperature was maintained at 37°C. Using 3T GE Signa Excite clinical 
scanner with a dedicated mouse coil (Rapid MR International, Germany), functional parameters 
were recorded on weeks 1 and 4 after treatment. The following sequences were performed for 
MRI acquisitions: (1) DEMRI was performed following IP injection of 0.2mmol/kg gadopentetate 
dimeglumine (Magnevist, Berlex Laboratories) using gated fGRE-IR sequences with FOV 3.4cm, 
slice thickness 0.9mm, matrix 128x128, TE 5ms, TI 150-240ms, and FA 60°; and (2) cardiac MRI 
of volumes were performed using fSPGR with FOV 7cm, slice thickness 0.9 mm, matrix 256x256, 
TE 5.5ms, and FA 30. Coronal and axial scout images were used to position a 2-dimensional 
imaging plane along the short axis of the left ventricular (LV) cavity (Extended Data Figure h-j).  
Histology, Immunohistochemistry and Immunofluorescent staining Histological analysis 
(Mason’s trichrome staining) was performed according to standard protocols for paraffin 
embedded samples. For immunohistochemistry and immunofluorescent staining, embedded 
hearts were sectioned at a thickness of 7 µm, unless described otherwise. Antibodies used were 
as follows: 1:200 α-actinin (Sigma, A7811), 1:300 α-smooth muscle actin (Sigma A2547) 1:100 
phospho-Histone3 (rabbit Millipore 06-570), 1:300 phospho-Histone3 (mouse Abcam ab14955) 
1:100 WT1 (Abcam, ab15249), 1:100 (Fig. 1l-m) and 1:250 (Fig. 3m, n, Fig. 5n) Aurora B 
(Millipore 04-1036), 1:100 Tnnt2 (DSHB, Ct3), 1:100 Tnni3 (Abcam, ab56357), 1:200 PCM1 
(Sigma-Aldrich HPA023370), 1:200 FSTL1 (R&D MAB17381). At least 5 sections per heart were 
used per staining for Mason’s Trichrome staining and 3 sections per heart per staining for 
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immunohistochemistry and immunofluorescent staining, respectively. HRP Anti-rat secondary 
antibody (Jackson ImmunoResearch 712-036-153, 1:500) was used for immunohistochemistry, 
and respective fluorescent secondary antibodies (Life Technologies 1:200) were used for 
immunofluorescent staining. The Trichrome staining and immunohistochemistry images were 
taken using an upright Zeiss microscope and dissection scopes. The fluorescent images were 
taken using Apotome Optical Sectioning (Zeiss). An inclusion criterion for the patch engraftment 
was that the patch covered > 70% of the infarct (controlled by histology). TUNEL assay (Roche 
11684795910).and EdU assay (Life Technologies C10337) were performed as instructed.  
Lineage tracing experiments 
Epicardial lineage labeling was achieved by oral delivery of tamoxifen (4 mg) in eight-week old 
Wt1CreERT2/+;Rosa26RFP/+ mice with C57BL/6J and ICR mixed background (delivered 6 times for 
duration of 3 weeks and stopped 1 week before MI). Hearts were collected at 2 weeks after MI. 
Immunostaining of RFP for Wt1 linage cells, Fstl1 and Tnni3 shows that Fstl1 is absent in 
epicardial cells and their derivatives, but abundant in the myocardium after MI (Fig. 2l). 
Cardiomyocyte lineage labeling was achieved by injecting 4-OH tamoxifen intraperitoneally into 
eight-week old Myh6mERCremER:Rosa26Z/EG mice17 of C57BL6 background at a dose of 20 mg/kg/d 
for 2 weeks, and stopped 1 week before havesting cardiomyocytes (Extended Fig. 7a-f), or MI 
operation and patch grafting. 4 weeks after MI, the animals were collect for immunostaining (Fig. 
3q-v).  
 
 
 
TTC staining At day 2 post MI/patch treatment, the mouse hearts from all four groups were 
harvested and sectioned perpendicularly to the long axis into four sections (approximately 2 mm 
thick). The sections were placed in the wells of a 12-well cell culture plate and incubated with 1% 
2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich) solution for 15 mins at 37°C. 
Subsequently section were washed with PBS and visualized using a stereomicroscope and 
photographed with a digital camera (Extended Data Figure 6a, b).  
Vessel counting. Blood vessel density parameters were measured from histological sections of 
heart samples stained for von Willebrand factor (vWF) as a marker of endothelial cells in the 
vessel wall. Up to 60 sections were analyzed for each treatment group (4 mice in each group). 
Analysis was performed using ImageJ to calculate: 1) the total luminal area of blood vessels, and 
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2) the number of vessels that stained + for the vWF. In each case, a histogram of the vessel 
parameters as a fraction of total surface area analyzed was obtained and the mid-values plotted 
for each treatment group.  Statistical significance (p<0.05) of the differences from sham group 
was determined by one-tailed ANOVA (Fig. 3f-i). 
 
Cardiomyocyte proliferation quantification in vivo. Data collected from 5-7 hearts in each 
group (7 for MI+Patch+FSTL1, 5 for Sham, MI-only and MI+Patch) with 3 different cross sections 
(each section covered the infarct, patch, and separated by 250μm, between 1-2mm from the 
apex) counted exhaustively for total pH3+/α-actinin+, Aurora B+/α-actinin+, and pH3+/PCM1+ cells 
in each section, and normalized to myocardium area quantified by trichrome staining of immediate 
adjacent section (Fig 5j-p, and Extended Data Fig 5). . 
 
Enzyme-linked Immunosorbent Assay. In order to assess the FSTL1 retention within the 
engineered patch system in vitro, collagen scaffolds laden with FSTL1 (5 µg/ml) were immersed 
in PBS and shaken for various times (0, 12 hours, 1 day, and 21 days) at 37oC and the FSTL1 
concentration was determined using Enzyme-linked Immunosorbent Assay kit (USCN Life 
Science, Inc., Houston, USA). The detection limit for this technique was 0.50 ng/ml. Scaffolds 
were pretreated with 1 mg/ml collagenase type I (Sigma Aldrich, MO, US) and 5 mg/ml 
hyaluronidase (Sigma Aldrich, MO, US) dissolved in phosphate buffered saline for 5 minutes 
followed by centrifugation at 5,000×g for 20 minutes. 
 Aliquots of 100 μl of the collected samples were added to the 96-well plates and incubated for 2 
hours at 37ºC. Then, 100µL of the prepared detection reagent A were added to the wells followed 
by 1 hour incubation at same temperature. After aspiration and washing 3 times, 100 µl of the 
prepared detection reagent B was added to the wells and incubated for 30 minutes at 37ºC. After 
aspiration and washing 5 times, 90µL of substrate solution was added to the wells following by 
incubation for 25 minutes at 37ºC. 50µL of stopping solution was added to the wells and the 
absorbance of each well was read at 450 nm, immediately. The concentration of FSTL1 was 
defined using standard curve of the standard solutions. The test was performed 4 times 
(Extended Data Fig. 3a). 
 
Application of the patch in a swine model of ischemia-reperfusion. The swine study was 
performed by inflation of a percutaneous coronary angioplasty dilation catheter to occlude the 
LAD in Yorkshire pigs (45 days old). Occlusion time of 90 mins was followed by fully reperfusion 
to mimic the clinical MI disease model. One week after MI, a left thoracotomy was performed and 
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the patch (6-cm diameter) was sutured onto the infarct. Animal groups included: sham controls, 
I/R with no treatment (n=3), I/R treated with patch alone (I/R+Patch, n=1), and I/R treated with 
patch laden with FSTL1 (I/R+Patch+FSTL1, n=2). EdU delivery: 250 mg/week EdU was infused 
into circulation during the 4-week time course of study (week 1 to week 5 post I/R), using osmotic 
mini pumps (fig. 5). 
 
Animal Compliance 
The procedures involving animal use and surgeries were approved by the Stanford Institutional 
Animal Care and Use Committee (IACUC). Animal care and interventions were provided in 
accordance with the Laboratory Animal Welfare Act (C57BL/6J wildtype mice (Fig. 1p-t, Fig. 2h-
k, Fig. 3a-p, Extended Data Fig. 3-6) Myh6mERCremER:Rosa26Z/EG. C57BL/6J mice (Fig. 3q-v, 
Extended Data Fig. 7a-f)  Yorkshire pigs (Fig. 5)). 
The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of 
Boston University (wildtype and Fstl1-TG C57BL/6J mice, (Extended Data Fig. 2, Fig. 3c)).. 
Mice were used in accordance with the guidelines of the Institutional Animal Care and Use 
Committee (IACUC) of the Institute for Nutritional Sciences, Shanghai Institutes for Biological 
Sciences, Chinese Academy of Sciences (Tnt-Cre;Rosa26mTmG/+, Wt1CreERT2/+;Rosa26mTmG/+.mice 
(C57BL/6J and ICR mixed background)  (Fig. 1j-m) Wt1CreERT2/+;Rosa26RFP/+ mice (C57BL/6J and 
ICR mixed background) (Fig. 2l) 
All animal study was approved by the Institutional Animal Care and Use Committee (IACUC) of 
Sanford-Burnham-Prebys Medical Discovery Institute. All animal procedures performed conform 
the NIH guidelines (Hsd:SD rats (Fig. 4g, m, n, Extended Data Fig. 7g-j)). 
Statistical analysis  The number of samples (n) used in each experiment is recorded in the text 
and shown in figures. All in vitro experiments have been done at least twice independently. Gene 
expression experiments have been done 3 times independently and EdU proliferation assays and 
cell size measurement have been done more than 10 times independently.  Sample size was not 
pre-determined, with retrospective analysis of significantly different results in most in vitro studies 
using Gpower 3.1 produces power > 0.8. Sample sizes for animal studies were estimated. 
Animals which did not survive up to 4 weeks after surgery were excluded from functional and 
histological studies. Randomization was not applied. Blinding to group allocation was practiced 
between animals surgery and results analysis of mouse myocardial infarction experiments. The 
values presented are expressed as means ± SEM. The rationale to use means ± SEM instead of 
SD is that SEM quantifies uncertainty in an estimate of the mean whereas SD indicates dispersion 
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of the data from mean. In other words, the SEM provides an estimate of the reported mean value, 
while the SD gives an idea of the variability of single observations. Normal distribution were tested 
and confirmed in automatic analysis of mCMsESC (Fig. 1c, g, i, Fig. 2d, f, g, Fig. 4d, e, j, k, l, m, 
n, Extended Data Fig. 1, 7h, j). We did not estimate variations in the data. The variances are 
similar between the groups that are being statistically compared. One-way ANOVA with multiple 
comparisons (Fig. 1r, 3, Extended Data Fig. 2b, d, 4, 5, 6) and student T-test (Fig. 1a-m, 2, 4, 
Extended Data Fig. 2e-n, 7) were used to test for statistical significance (P < 0.05). Survival 
curve were generated by Kaplan-Meier method using PRISM (GraphPad) and Log-rank (Mantel-
Cox) test was used to test the significant differences between the survival of mice in different 
conditions (Fig. 3a).  
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Extended Data Figure Legends 
 
Extended Data Figure 1. Characterization of mCMsESC cells used in this study.  
 
a) Schematic time-line of cell preparation and treatment.  
b-d) Immunostaining of α-actinin of mCMsESC, showing that the majority of the cells are α-
actinin+(b), and the α-actinin lacks striation structures (c).  d) Immunostaining of α-smooth muscle 
actin (αSMA) of mCMsESC, showing the majority of the cells are αSMA+, unlike mature 
cardiomyocytes with no SMA expression38.  
e-f) Automatic detection of EdU incorporation in mCMsESC. Captured image of mCMsESC treated 
with 10μg/ml EdU for 24 hours, stained with EdU, α-actinin and DAPI using InCell 1000  (General 
Electric) (e). Overlay of masks of EdU, α-actinin and DAPI channels with automatic detection 
software (f).  
g) EdU incorporation profile of mCMsESC over time. mCMsESC are treated with 10μg/ml EdU for 24 
hours at time 0 hour, 24 hours, 48 hours, and 144 hours. The percentage of EdU+/α-actinin+ 
cardiomyocytes of all α-actinin+ cardiomyocytes is calculated for each time period. Note the 
decrease of EdU incorporation rate over time.  
h,i) Fluo 4 calcium images of mCMsESC, with baseline background image (h) and peak image (i). 
j) Comparison of representative calcium transients of mCMsESC (red) and neonatal rat ventricular 
cardiomyocytes (NRVC, blue). Note the reduced amplitude, slower rate of up and down strokes, 
and elongated duration of the calcium transient in mCMsESC compared to NRVC, suggesting 
immature calcium handling in mCMsESC.   
 
In all experiments, FSTL1 was added one day after plating of the mCMsESC (time 0-24 in this 
figure).  
 
 
Extended Data Figure 2. Myocardial overexpression of Fstl1 (Fstl1-TG) mice after 
permanent LAD ligation.  
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a-d) Fstl1 protein expression kinetics after myocardial infarction. Fstl1-TG mice (C57/Bl6 
background) and littermate wild type (WT) mice underwent LAD ligation. Heart tissue and serum 
were collected at baseline, day 1, day 3, day 7 and day 28 after surgery.  Fstl1 protein levels in 
ischemic area (IA) and remote area (RM) of heart were analyzed by Western blotting (a). Fstl1 
expression expressed relative to tubulin levels is reported (b). Fstl1 serum levels were analyzed 
by Western blotting (c). Also shown in Ponceau-S staining to indicate equal loading of serum.  
Quantification of serum Fstl1 level is shown in (d). n>3 in all groups. *: P<0.05 compared to WT 
baseline, #: P<0.05 compared to Fstl1-TG baseline. ANOVA was used for statistical significance 
(P<0.05).  
e-j) Morphometric and functional response of Fstl1-TG mice to permanent LAD ligation at 
long-term. Representative Masson’s trichrome staining of WT (e) and Fstl1-TG (f) 4 weeks after 
MI. Quantification of content in fibrotic tissue at week 4 after MI (g). Echocardiographic 
measurement of left ventricular internal dimension in systole (LVIDs) (h), and left ventricular 
internal diameter in diastole (LIVDd) (i) at weeks 2, 4 after MI.  Echocardiographic determination 
of fractional shortening (FS%) in the indicated genotypes at 2 and 4 weeks after MI (j). 
(k-n) Double immunofluorescent staining of α-actinin (cardiomyocytes) and pH3 (mitosis) (k) 
and α-actinin (cardiomyocytes) and von Willebrand factor (vascular endothelial cells) (m) in the 
Fstl1-TG and WT mice, quantified in (I, n). n=5, *, significantly different (P<0.05) from WT. 
 
Extended Data Figure 3. Patch+FSTL1 attenuated fibrosis after MI  
a-f) FSTL1 retention in the patch in vitro and in vivo. a,b) Enzyme-linked immunosorbent 
assay used to measure the amount of FSTL1 retained within collagen scaffolds exposed to PBS 
in vitro for different time intervals (0-21 days) (a).  The Table lists the initial and final FSTL1 
concentration, as well as the release values within the first 24 hours (b). c-f) FSTL1 
retention in the patch in vivo. Representative images of Fstl1 immunostaining in the indicated 
animal treatment groups, week 4 after surgery.  Note that, while Fstl1 is expressed in the 
uninjured epicardium (arrow in the inset in c), its expression became undetectable within the 
infarct area after MI (d).  Similarly, no FSTL1 was detected in the MI+Patch animals (e), while it 
still persists (red staining) in the patch area of the MI+Patch+FSTL1 group (f).  
 
g) Representative Masson’s Trichrome staining on serial cross sections of hearts under 4 
conditions (sham, MI only, MI+patch and MI+patch+FSTL1) 4 weeks after MI. Note the severe 
fibrosis in MI only condition, and reduced fibrosis in MI+Patch condition, and further reduction in 
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MI+Patch+FSTL1 condition, quantified in Fig. 3d. 
 
h-j) Representative MRI images from the mouse MI-only, MI+patch and MI+Patch+FSTL1 
treatment groups showing the 3D-FSPGR (fast spoiled gradient-echo) images and the delayed 
enhancement images utilizing gadolinium contrasting agents, confirming a reduction in infarct 
area (demarcated in green) and preserved contractility (Suppl. Videos 3-5). 
 
k) Trichrome staining of infarct and border zone of the indicated treatments demonstrates the 
integration of the patch with the host tissue and massive patch cellularization by the native cardiac 
cells. Observe the abundant muscle (red) inside the patch and in the border zone of the 
patch+FSTL1 treated animals (three right panels, green arrowheads).  
 
Extended Data Figure 4.  Analysis of patch+FSTL1 function in the mouse model of 
ischemia/reperfusion (I/R) with delayed patch grafting. 
 
a-c) Heart function evaluation for sham, I/R, and I/R treated with patch+FSTL1, at end- diastolic 
and systolic, pre-grafting (a, 1 week post injury), 2 weeks post patch implantation (b), and 4 
weeks post grafting (c). Values were normalized by dividing to pre-surgery baseline values for 
each individual animal.  d) Absolute values of fractional shortening (FS, %) at different times pre 
and post I/R as evaluated by echocardiography of mice from a-c. Abbreviations same as in Fig. 3. 
*: p<0.05 compared to sham and ●: p<0.05 compared to I/R. e) co-immunofluorescence staining 
of DNA duplication marker phospho-Histone3 Ser10 (pH3, green) and α-actinin (red) in the border 
zone of Patch+FSTL1 treated heart 4 weeks after MI. f) Quantification of incidence of pH3+, α-
actinin+ double positive cells in the 3 experimental groups. Data collected from 3 hearts in each 
group with 3 different cross sections counted for total pH3+, α-actinin+ cells in each heart.  *: 
statistically different from all other groups, P<0.05.  
 
Extended Data Figure 5. Representative images and quantification of cardiomyocyte 
proliferation in vivo after Patch+FSTL1 treatment 
 
a-h) Immunostaining of the cardiomyocyte marker α-actinin (red) in the infarct area (b-d) and co-
immunofluorescence staining of DNA duplication marker phospho-Histone3 Ser10 (pH3, green) 
and α-actinin (red) in the border zone (f-h), in the 4 treatment groups analyzed 4 weeks post-MI, 
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compared to sham-operated animals (a,e).  Insets in (a-d) show lower magnification images with 
broken lines demarcating the border between the patch and host tissues.  Arrowheads in (g,h) 
indicate α-actinin+ cardiomyocytes with pH3+ nuclei,.  
i-k) Representative images of pH3+ cardiomyocytes in a Patch+FSTL1 treated heart. Masson’s 
Trichrome staining of a heart after MI 4 weeks treated with Patch+FSTL1 (i). The adjacent slide 
was stained for α-actinin in (j), corresponding to the black box area with infarction and the patch 
in (i). The spotted line in (j) indicates the boundary between the heart and the patch. The adjacent 
slide was stained for α-actinin and pH3, and all α-actinin+, pH3+ double positive cardiomyocytes 
found were shown in (k) (white arrowhead), with each image corresponding to the area in 
numbered white boxes in (j). 
 
l-n) Quantification of cardiomyocyte proliferation measured in 3 cross sections covering the 
infarct, patch, and separated by 250μm, between 1-2mm from the apex in each heart (Fig. 3j). 
Data collected from 5-7 hearts in each group with the 3 cross sections counted exhaustively for 
incidence of α-actinin+ cells positive for pH3 (l), midbody-localized Aurora B kinase between α-
actinin+ cells (m), and double-positive cells for pH3 and  the nuclear cardiomyocyte maker PCM1 
(n), and normalized to myocardium area quantified by trichrome staining of immediate adjacent 
section. *: statistically different from sham, P<0.05. **: statistically different from all other groups, 
P<0.05. 
o) Quantification of hypertrophy in all experimental groups, measured by counting cardiomyocytes 
in areas of intraventricular wall with perpendicular cross sections of cardiomyocytes in all hearts 
analyzed for cardiomyocyte proliferation. No significance were found between samples. 
p-r) Quantification of incidence of α-actinin+ cells positive for pH3 (p), midbody-localized Aurora B 
kinase between α-actinin+ cells (q), and double-positive cells for pH3 and  the nuclear 
cardiomyocyte maker PCM1 (r) measured in l-m to total number of cardiomyocytes, calculated 
using hypertrophic analysis results in o. *: statistically different from sham, P<0.05. **: statistically 
different from all other groups, P<0.05. 
s, t) Quantification of incidence of α-actinin+ cells positive for pH3 (s) and midbody-localized 
Aurora B kinase between α-actinin+ cells (t), separated by their localization in the border zone or 
infarcted area. Note the majority of proliferation quantified by both methods are located in the 
border zone, *: statistically different from all other groups, P<0.05. 
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Extended Data Figure 6. Effect of implantation of patch+FSTL1 on apoptosis and 
inflammation.  
 
a) Representative TTC staining of day 2 post MI/patch treatment of all four groups (sham, MI, 
MI+Patch, MI+Patch+FSTL1). b) Quantification of area at risk comparing all 4 groups. Data 
collected from 4 hearts in each group, with 4 cross sections, approximately 2 mm thick each, 
encompassing each heart. *: statistically different from the sham, P<0.05.  
c, d) Representative image of TUNEL assays (TUNEL, green, α-actinin, red) comparing hearts 2 
days after MI with patch alone and patch+FSTL1. e) Quantification of TUNEL+, α-actinin+ in 
infarcted area, as percentage of total number of cardiomyocyte. No difference is observed 
between MI+Patch and MI+Patch+FSTL1 conditions. Data collected from 3 hearts in each group 
with 3 different cross sections (same as in Fig. 3j) Ten 0.09mm2 images were taken from 
infarcted area of each section and counted for TUNEL+, α-actinin+ and total α-actinin+ cells. 
f-j) TUNEL staining for cell death and α-actinin staining for cardiomyocytes were performed on 
hearts treated with patch-only and patch+FSTL1 at day 4 and day 8 after MI (f-i). Minial TUNEL+, 
α-actinin+ cells are detected while there are signification amount of TUNEL+, α-actinin- cells. 
Quantification of all TUNEL+ nuclei showed no significant differences between Patch and 
Patch+FSTL1 treated hearts at both time points (j).  
k-o) Immunostaining of F4/80 for macrophages and α-actinin for cardiomyocyte were performed 
on the same hearts as in panels a-d (k-n).  Quantification of F4/80+ cells showed no significant 
differences between Patch and Patch+FSTL1 treated hearts at both time points (o). 
 
 
Extended Data Figure 7. FSTL1 does not induce proliferation in adult and neonatal 
cardiomyocytes, or cardiac progenitor cells. 
a-f) Adult cardiomyocytes derived from mouse primary isolation. a) Visualization of GFP+ 
cardiomyocytes isolated from Myh6mERCremER:Rosa26Z/EG mice treated with 4-OH-tamoxifen (OH-
Tam) in 3D-collagen patches. b-d) Gene expression changes in adult cardiomyocyte treated with 
FSTL1, including proliferation (b), cardiac-specific (c), and hypertrophy (d) markers.  Note no 
changes in expression of cardiac specific genes, no increase in cell cycle markers (consistent with 
undetectable Ki67 immunostaining), and decreased hypertrophy markers (n=3). Cardiomyocytes 
were embedded within 3D patch were treated with FSTL1 (10ng/ml) for duration of 7 days with 
media change every 2 days.  
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e,f) FUCCI assay in 3D-cultured adult cardiomyocytes, conducted 1 week after the 3D 
culture. e) Treatment with FSTL1 was performed for 7 days with media change every 2 days. f) 
Adult cardiomyocytes 3D-cultured control in absence of FSTL1. Note no detectable sign of 
cardiomyocytes in S/G2/M phases (GFP+) in either condition. Purple arrows point to purple-
colored nuclei resulting from co-localization of Hoechst (blue) and G1 phase FUCCI (red) labeling. 
(g-j) Primary neonatal rat ventricular cardiomyocytes (NRVC). g,h) Freshly isolated NRVCs  
stimulated with FSTL1 for 48 hours with 10μg/ml EdU, and stained for α-actinin (red) and EdU 
(green). Percentages of EdU+/α-actinin+ cardiomyocytes of all α-actinin+ cardiomyocytes are 
quantified (h).  i, j) NRVCs stimulated with FSTL1 for 48 hours, and stained for α-actinin (red) and 
pH3 (green). Percentages of pH3+/α-actinin+ cardiomyocytes of all α-actinin+ cardiomyocytes are 
quantified (j). No increase of proliferation is found upon FSTL1 treatment. (n=4) *: statistically 
different from control, P<0.05.  
k-m) Sca1+ progenitor cells18  were starvation-synchronized for 48 hours and stimulated with 
FSTL1 or control growth medium for 72 hours in presence of EdU. Clone 3 was obtained by 
clonal growth from the Lin-Sca1+SP fraction. Sca1 pool was obtained from lin-Sca1+ without 
clonal growth.  k) EdU and DAPI staining of Sca1+ cells after 72 hours treatment.  l) Percentage 
of EdU+ Sca1+ cells after 72 hours treatment. FSTL1 concentration: 0, 1, 10, 100 ng/ml.  
Abbreviations: SS, serum starvation; CGM, control growth medium. m) Number of Sca1+ cells 
after 72 hours FSTL1 treatment (n=5). No significant change is found upon FSTL1 treatment.  
 
Extended Data Table 1. Raw echocardiography values (average ± SEM) obtained at days 0 
(baseline), 14, and 28 post treatment in a mouse model of permanent LAD ligation. The patch 
was implanted simultaneously with injury. *: statistically significant difference (P<0.05) in 
comparison with Sham. ●: statistically significant difference (P<0.05) in comparison with MI-only. 
■: statistically significant difference (P<0.05) in comparison with MI+Patch. ▲: statistically 
significant difference (P<0.05) in comparison with MI+Patch+CM. 
Extended Data Table 2. Raw echocardiography values (average ± SEM) in a long term (months 
2 and 3) post treatment, in a mouse model of permanent LAD ligation. The patch was implanted 
simultaneously with injury.  *: statistically significant difference (P<0.05) in comparison with Sham. 
●: statistically significant difference (P<0.05) in comparison with MI-only. ■: statistically significant 
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difference (P<0.05) in comparison with MI+Patch. ▲: statistically significant difference (P<0.05) in 
comparison with MI+Patch+CM. 
Extended Data Table 3. Raw echocardiography values (average ± SEM) of delayed grafting in a 
mouse model of ischemia/reperfusion.  Data obtained at baseline (pre-injury, pre-grafting), weeks 
1 (post injury, pre grafting) and weeks 3, 5 (post-injury, post-grafting). The patch was implanted 1 
week after injury. *: statistically significant difference (P<0.05) in comparison with Sham. ●: 
statistically significant difference (P<0.05) in comparison with MI-only. ■: statistically significant 
difference (P<0.05) in comparison with MI+Patch. ▲: statistically significant difference (P<0.05) in 
comparison with MI+Patch+CM. 
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